Tolerance & Cross-Tolerance
How tolerance develops, resets, and creates cross-tolerance between substances. Understanding tolerance mechanics is critical for dose adjustment and preventing accidental overdose.
Tolerance loss kills. When tolerance drops (after a break, hospitalization, incarceration, or withdrawal), your previous dose can become a lethal dose. This is the leading mechanism of opioid overdose deaths and applies to depressants as well.
key concepts
ToleranceReduced response to a substance after repeated use. More of the substance is needed to achieve the same effect. Tolerance is substance-specific and develops at different rates for different effects.
Cross-toleranceWhen tolerance to one substance reduces the effects of another substance that acts on the same receptor system. For example, LSD tolerance reduces the effects of psilocybin because both act on 5-HT2A receptors.
Asymmetric toleranceWhen tolerance develops faster to desirable effects than to dangerous side effects. This is the mechanism behind many overdose deaths — users increase their dose to chase diminishing highs while unknowingly narrowing their safety margin.
Reverse tolerance (sensitization)When repeated use increases sensitivity to certain effects. Rare but clinically important: stimulant psychosis shows sensitization (lower doses trigger psychosis with repeated use), and alcohol-induced liver damage reduces metabolic tolerance over time.
Incomplete cross-toleranceCross-tolerance is rarely 1:1. When switching between substances in the same class (e.g., switching opioids), tolerance does not fully transfer. Standard practice is to reduce the equivalent dose by 25–50% when switching.
Classic psychedelics (LSD, psilocybin, mescaline)
full toleranceImmediate (within hours of a single dose)
cross-tolerance–Strong cross-tolerance between all serotonergic psychedelics (LSD ↔ psilocybin ↔ mescaline)
–Partial cross-tolerance with DMT (inconsistent, some users report it)
–No cross-tolerance with MDMA, ketamine, or cannabis
Psychedelic tolerance develops faster than almost any other drug class. Taking the same dose the next day typically produces 50–70% reduced effects. This rapid tolerance is actually protective — it makes compulsive redosing ineffective. Full reset typically requires 2 weeks between uses.
MDMA
full toleranceDevelops over multiple sessions (not single-use)
full reset∼3 months (the “3-month rule”)
cross-tolerance–Cross-tolerance with other serotonin releasers (MDA, methylone)
–No cross-tolerance with psychedelics despite shared serotonergic effects
asymmetric tolerance — MDMA tolerance is asymmetric: users develop tolerance to positive effects (empathy, euphoria) faster than to negative effects (neurotoxicity, cardiovascular strain). Chasing the “first time” feeling with higher doses increases harm without restoring the original experience.
The 3-month minimum interval is based on serotonin system recovery time, not tolerance alone. More frequent use leads to diminishing positive effects, increasing negative effects, and cumulative neurotoxicity. There is no “trick” to reset MDMA tolerance faster — only time.
Opioids
full toleranceDays to weeks of regular use
full reset∼1–2 weeks (but highly variable)
cross-tolerance–Cross-tolerance between all mu-opioid agonists (heroin, morphine, oxycodone, fentanyl, etc.)
–Cross-tolerance is incomplete — switching opioids typically requires 25–50% dose reduction
–Kratom has partial cross-tolerance due to mu-opioid activity
asymmetric tolerance — CRITICAL: Tolerance to euphoria develops faster than tolerance to respiratory depression. This means that while users feel they need more to get high, their margin of safety between an effective dose and a lethal dose narrows with every increase. Additionally, tolerance to overdose protection drops MUCH faster than cravings during abstinence — this is why post-withdrawal relapse is the highest-risk period for fatal overdose.
Opioid tolerance loss is the single most dangerous tolerance phenomenon. Even 3–5 days of abstinence (jail, hospital, withdrawal attempt) can reduce tolerance enough that your previous dose becomes lethal. If you relapse after any period of abstinence, start at a fraction of your previous dose. Have naloxone available.
Stimulants (amphetamines, cocaine)
full toleranceVariable — develops to different effects at different rates
half reset∼1–3 days (cocaine) / 3–7 days (amphetamines)
full reset∼1–2 weeks (cocaine) / 2–4 weeks (amphetamines)
cross-tolerance–Partial cross-tolerance between amphetamines and methylphenidate
–Limited cross-tolerance between cocaine and amphetamines (different mechanisms)
–MDMA shares some dopaminergic cross-tolerance
asymmetric tolerance — Tolerance develops to euphoria and appetite suppression faster than to cardiovascular effects (elevated heart rate, blood pressure). Increasing doses to chase euphoria increases cardiac risk disproportionately. Stimulant psychosis threshold also lowers with repeated use (reverse tolerance / sensitization).
Cocaine has an unusual tolerance profile: acute tolerance develops within a single session (first hit of the night is typically strongest), but chronic tolerance from daily use builds more slowly. Binge patterns are particularly dangerous because they combine acute tolerance-driven redosing with cumulative cardiovascular strain.
Benzodiazepines
full tolerance2–4 weeks of daily use for sedation; slower for anxiolytic effects
half resetVariable (depends on duration of use)
full resetWeeks to months (proportional to duration of use)
cross-tolerance–Full cross-tolerance with other benzodiazepines
–Cross-tolerance with alcohol, barbiturates, and other GABAergic depressants
–Partial cross-tolerance with GHB/GBL
–Z-drugs (zolpidem, zopiclone) share cross-tolerance
asymmetric tolerance — Tolerance to sedation develops faster than tolerance to anxiolytic (anti-anxiety) effects. This is why patients may feel the drug “stopped working” for sleep while it is still providing anxiety relief. Dose escalation to restore sedation increases dependence and withdrawal severity.
Benzodiazepine-alcohol cross-tolerance is critically important: someone tolerant to benzodiazepines will have reduced response to alcohol’s sedation but NOT to alcohol’s organ toxicity. The lethal combination risk persists regardless of tolerance.
Cannabis
full tolerance1–2 weeks of daily use
full reset∼2–4 weeks (receptor upregulation studies show ∼28 days)
cross-tolerance–Cross-tolerance with synthetic cannabinoids (which are far more potent and dangerous)
–No cross-tolerance with other drug classes
asymmetric tolerance — Tolerance to the “high” (euphoria, altered perception) develops faster than tolerance to cognitive impairment. Regular users may feel functionally normal while still being measurably impaired on tasks requiring reaction time and working memory.
CB1 receptor downregulation begins to reverse within 48 hours of stopping and is largely complete by 4 weeks. A “tolerance break” (T-break) of 2–4 weeks will substantially restore sensitivity. Even 48–72 hours produces noticeable reduction in tolerance.
Ketamine / Dissociatives
full toleranceDevelops with regular use over days to weeks
cross-tolerance–Cross-tolerance between NMDA antagonists (ketamine ↔ DXM ↔ MXE ↔ PCP)
–Nitrous oxide has different mechanism — limited cross-tolerance
–No cross-tolerance with psychedelics or other drug classes
asymmetric tolerance — Tolerance to dissociative and psychedelic effects develops, but tolerance to bladder toxicity does not. Frequent ketamine users who increase doses to overcome tolerance accelerate bladder damage. Ketamine cystitis can be irreversible.
Ketamine tolerance can develop rapidly with frequent use (multiple times per week). Unlike many substances, the organ damage (bladder, urinary tract) is dose-dependent and cumulative regardless of tolerance. Switching to higher doses or more frequent use to overcome tolerance is particularly dangerous for this reason.
Tolerance information here represents general patterns observed in clinical and self-report data. Individual tolerance development and reset varies significantly based on genetics, frequency and duration of use, dosage, and overall health.
After any period of reduced use or abstinence, always start at a lower dose. Tolerance loss is invisible — you cannot feel that your safety margin has narrowed until it is too late.